US 11613586
Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 11613586 (Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies) held by Takeda Pharmaceutical Company Limited expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61P, A61P1/00